dc.contributor.author | Vyas, Madhusudan | |
dc.contributor.author | Fagan, Jessica | |
dc.contributor.author | Shaikh, Shamim | |
dc.date.accessioned | 2019-10-02T21:47:04Z | |
dc.date.available | 2019-10-02T21:47:04Z | |
dc.date.issued | 2019-08-31 | |
dc.identifier.uri | https://hdl.handle.net/10652/4714 | |
dc.description.abstract | Objective
To evaluate the impact/effects of Lutetium-177-PSMA based treatment in improving the quality of life in patients with advanced stage of prostate cancer (mCRPC)
Methodology
Epidemiology (Global data)
Epidemiology (NZ Data)
Diagnosis and staging
Treatment plan
Metastatic disease(mCRPC)
Metastatic disease(mCRPC)
Metastatic disease(mCRPC) treatment algorithm
Metastatic disease(mCRPC) treatment review of literature
Prostate specific membrane antigen (PSMA) and mCRPC
Various Prostate specific membrane antigen (PSMA) ligands and radionuclides suitable for labelling
Lu-177 PSMA based Metastatic disease(mCRPC) treatment review of literature
Lu-177-PSMA Treatment outcomes
Lu-177 based therapeutic radiopharmaceuticals based treatment outcomes
Physiological outcomes of the treatment, at our clinical site
QoL, Pain and PSA levels; relative comparison
PSA response and QoLoutcomes to Lu-177-PSMA, at our clinical site
Third line treatment v/s Lu-177-PSMA
Third line treatment v/s Lu-177-PSMA;Feedback from patients
Conclusion
Reference | en_NZ |
dc.language.iso | en | en_NZ |
dc.rights | All rights reserved | en_NZ |
dc.subject | cancer patients | en_NZ |
dc.subject | prostate cancer | en_NZ |
dc.subject | theranostics | en_NZ |
dc.subject | radionuclide therapy | en_NZ |
dc.subject | Lu-177 | en_NZ |
dc.subject | Lutetium-177 | en_NZ |
dc.subject | neuroendocrine tumours (NETs) | en_NZ |
dc.subject | New Zealand | en_NZ |
dc.subject | metastatic castration-resistant prostate cancer (mCRPC) | en_NZ |
dc.subject | mCRPC | en_NZ |
dc.title | A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers : positive impacts of the Lu177- PSMA treatment in the advanced stage of prostate cancer | en_NZ |
dc.type | Conference Contribution - Oral Presentation | en_NZ |
dc.date.updated | 2019-09-23T20:40:42Z | |
dc.rights.holder | Authors | en_NZ |
dc.subject.marsden | 1112 Oncology and Carcinogenesis | en_NZ |
dc.subject.marsden | 110313 Nuclear Medicine | |
dc.identifier.bibliographicCitation | Vyas, M., Fagan, J., & Shaikh, S. (2019, September). A ray of hope patients with metastatic castration-resistant prostate cancer (mCRPC) sufferers: Positive impacts of the Lu177- PSMA Treatment in the advanced stage of Prostate cancer. Paper presented at the NZIMRT/ANZSNM-2019, Rotorua, New Zealand. | en_NZ |
unitec.publication.title | NZIMRT/ANZSNM-2019 | en_NZ |
unitec.conference.title | NZIMRT/ANZSNM-2019 | en_NZ |
unitec.conference.org | New Zealand Institute of Medical Radiation Technology (NZIMRT) | en_NZ |
unitec.conference.org | Australian and New Zealand Society of Nuclear Medicine (ANZSNM) | en_NZ |
unitec.conference.location | Rotorua, New Zealand | en_NZ |
unitec.conference.sdate | 2019-08-30 | |
unitec.conference.edate | 2019-09-01 | |
unitec.peerreviewed | yes | en_NZ |
dc.contributor.affiliation | Unitec Institute of Technology | en_NZ |
unitec.identifier.roms | 64435 | en_NZ |
unitec.identifier.roms | 64452 | |
unitec.institution.studyarea | Health Sciences | |